e Following the molecular cloning in the early 1990s of the metabotropic glutamate receptors (mGlu1-8), research that focused on the physiology, pharmacology and function of these receptors revealed their potential role in CNS disorders. Numerous psychiatric and neurological disorders are indeed linked to changes in excitatory processes, in which glutamate plays a key role. In contrast to ligand-gated ion channels [N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) and kainate], which are responsible for fast excitatory transmission, mGlu receptors have a more modulatory role, by contributing to fine-tuning of synaptic efficacy, and control of the accuracy and sharpness of the transmission. Given the fact that the mGlu receptors are Gprotein coupled, they obviously constitute new 'drugable' targets for the treatment of various CNS disorders. Due to the recent emergence of subtype-specific ligands for Group I and II mGlu receptors, this review will concentrate on the molecular characteristics, brain localization, pharmacology and physiological role of these receptors, in order to provide further insights into their therapeutic potential.
It is well established that glutamate is the main excitatory neurotransmitter in the brain. Until the mid1980s it was believed that the effects of glutamate are mediated exclusively via a limited number of distinct ionotropic glutamate (iGlu) receptor-channels, namely: NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid) and kainate receptors (for a review, see: Dingledine et al., 1999) (Fig.  1) . However, at that time several studies suggested that glutamate could also stimulate phosphoinositide turnover, i.e. a typical characteristic of a G-protein-coupled receptor (GPCR; Sladeczek et al., 1985; Nicoletti et al., 1986; Sugiyama et al., 1987) . The search for the molecular identity of such a GPCR culminated in the cloning of a receptor now identified as the mGlu1a receptor (Houamed et al., 1991; Masu et al., 1991) . In the following 5 years, additional mammalian receptors were cloned, and to date there are eight known mGlu receptors, which are classified into three groups of receptors based on sequence homology, preferred signal transduction pathway and pharmacology (Conn and Pin, 1997) . Group I includes mGlu1 and mGlu5 receptors, which are coupled via Gq to phospholipase C. Group II includes mGlu2 and mGlu3 receptors, and Group III includes mGlu4, 6, 7 and 8 receptors; all are coupled to Gi and inhibit stimulated cAMP formation when expressed in cell lines ( Fig. 1 ; for differentiation see also: De Blasi et al., 2001) .
Receptor structure and function
All mGlu receptors have a large extracellular ligandrecognition N-terminal domain and seven transmembrane-spanning regions that are connected by three intracellular and three extracellular loops, with a number of conserved cysteine residues (reviewed by Hermans and Challiss, 2001) (Fig. 2) . The extracellular ligandrecognition N-terminal domain has a so-called bi-lobed structure ( = fly-trap function), with an open or closed configuration in the absence or presence of an agonist, respectively (Galvez et al., 1999; Kunishima et al., 2000) ( Fig. 2) . These particular structural features resemble those seen in bacterial periplasmic binding proteins and are thought to have a sensory function for nutrient recognition and cellular uptake (reviewed by Quiocho and Ledvina, 1996) . Modelling studies have indeed indicated that the N-terminal extracellular domain of the mGlu1 receptor has structural similarities with such bacterial plasmic binding proteins (Costantino and Pellicciari, 1996; Costantino et al., 2001) . Like the bacterial plasmic binding proteins, the two globular lobes are linked by a hinge region that allows different conformational positions (open and closed) . Upon binding of the agonist within the crevice that separates the two lobes, the flytrap closes and the agonist is thought to stabilize the closed conformation by making bonds with residues of both lobes (Bessis et al., 2000; Kunishima et al., 2000) .
Recent findings indicate that functional mGlu1 and mGlu5 receptors may exist predominantly as homodimers in the brain (Romano et al., 1996) (Fig. 2) . The structure of the dimeric extracellular domain in the absence or presence of glutamate is quite distinct: glutamate not only stabilizes the closed state of the extracellular domain, but in addition changes the respective orientation of both extracellular regions. As a consequence, the C-terminal part of the extracellular domain, which is normally connected to the seven transmembrane region, moves closer by more than 25 Å. This conformational change may trigger the switch to the active state of the dimeric seven transmembrane region (Kunishima et al., 2000; also, reviewed by De Blasi et al., 2001; Jensen et al., 2002) .
mGlu-receptor interacting proteins
Group I receptors are known to have relatively long Cterminal intracellular tails (>300 residues; see above) which may interact with various proteins inside neurons.
One of the most interesting recent findings in this respect is the interaction of mGlu receptors with Homer proteins. The motif (Pro-Pro-X-X-Phe-Arg) mediating the interaction is found close to the C-terminus of the receptor (reviewed by Xiao et al., 2000) . Homer proteins can form dimers through coil-coil interactions and can potentially cross-link receptors to other large protein complexes. The interaction of mGlu receptors with Homer proteins thus enables mGlu receptors to have control over large protein complexes elsewhere in the membrane; for example, through specific membrane insertion and/or through specific neuronal location (Roche et al., 1999; Ango et al., 2000) . Moreover, recent findings have shown that the constitutive activity of Group I receptors is indeed controlled by Homer proteins, which bind directly to the C-terminal domains of the receptors (Ango et al., 2001 ). Disruption of this interaction induces constitutive activity of Group I receptors. Thus, metabotropic glutamate receptors can be activated directly by intracellular proteins, as well as by extracellular agonists. These identified intracellular proteins may provide new and interesting targets for modulating metabotropic glutamate receptors.
Regional expression of Group I and II mGlu receptors in the brain
We will focus on the distribution of mGlu receptors as determined by means of immunocytochemistry (mGlu-IR), and highlight the expression of Group I and II receptors in those regions that are relevant for the focus of this review ( Fig. 3 ; Table 1 ). For a detailed description and discussion of the expression of mGlu receptors, we refer to the recent review of Shigemoto and Mizuno (2000) .
Distribution of Group I receptors in the rat brain mGlu1 receptors mGlu1 receptors are expressed throughout the brain, and for detailed descriptions we refer to Martin et al. (1992) , Baude et al. (1993) , Fotuhi et al. (1993) and Petralia (1997) (Fig. 3a ; Table 1 ). Herein, we provide a general description of the distribution of mGlu receptors from the anterior to the posterior part of the brain. mGlu1 receptors are abundant in the main olfactory and accessory bulb of the olfactory system, and the Islands of Calleja. These receptors are moderately expressed in the olfactory tubercle. Low to moderate receptor levels are found in various neo-and limbic cortical regions; whereas certain regions of the hippocampus, in particular the dendritic field and hilus of the dentate gyrus, as well as the CA3 region, contain high levels. mGlu1 receptors are not expressed in the CA1 region. Low expression levels are found in the greater part of the septum, with the exception of the lateral septum, which expresses mGlu1 receptors highly. The amygdala and input nuclei of the basal ganglia (striatum and nucleus accumbens) show low expression levels; whereas the output structures of the basal ganglia (pallidal complex, subthalamic nucleus and substantia nigra) show moderate levels. The thalamus contains high levels of mGlu1 receptors, particularly the mediodorsal and ventrolateral nuclei, but these receptors are virtually absent in the hypothalamus and midbrain. The cerebellum also contains high levels, particularly in the molecular and Purkinje cell layers. Finally, moderate levels of mGlu1 receptors are found in the spinal cord (dorsal horn region).
mGlu5 receptors
For a detailed and systematic examination of mGlu5 receptor expression in the nervous system we refer to Shigemoto et al. (1993) and Romano et al. (1995) (Fig. 3b , Table 1 ). mGlu5 receptors are moderately expressed in the main and accessory bulb of the olfactory system, the anterior olfactory nucleus and the olfactory tubercle. The neo-and limbic cortex (layers I-VI), including the subiculum, entorhinal, cingulate and piriform cortical regions, contain moderate to high receptor densities. Within the hippocampus, high levels of mGlu5 receptors are found in the CA1 and CA3 region, as well as in the hilus and molecular layer of the dentate gyrus. Relatively low levels are found in the septum and basal forebrain, again with the exception of the lateral septal nucleus, which exhibits very high mGlu5 expression. The amygdala shows moderate receptor levels; whereas very high expression levels are found in the input regions of the basal ganglia (striatum and nucleus accumbens), and moderate levels in the output regions (pallidal and nigral complexes and subthalamic nucleus). The thalamus, hypothalamus, midbrain and cerebellum show low expression levels, but the spinal cord contains high levels of mGlu5 receptors, particularly in the dorsal horn.
Distribution of Group II receptors in the rat brain
For the original systematic description of the brain distribution of mGlu2 and mGlu3 receptors we refer to Ohishi et al. (1994) and Petralia (1996) . These authors used an antibody directed against the C-terminus of the rat mGlu2 receptor, but which recognizes both mGlu2 and mGlu3 receptors (see also Shigemoto and Mizuno, 2000) (Fig. 3c , Table 1 ). Moderate expression of these receptors is found in the olfactory system, including the main and accessory bulb, and the olfactory tubercle. The neocortex (layers I-VI), various limbic cortical regions, including the cingulate cortex and subiculum, parts of the CA1 and CA3 region, as well as the hilus and molecular layer of the dentate gyrus, contain high receptor levels. Low expression of mGlu2/3 receptors is found in the septum and the basal forebrain; whereas moderate to high expression is found in distinct regions of the amygdala, including the central and basolateral nuclei. High levels of mGlu2/3 receptors are found in the striatum and the nucleus accumbens, but the remaining areas of the basal ganglia show low expression levels. The thalamus exhibits moderate expression levels. Expression levels are very low in the hypothalamus and midbrain regions. Finally, moderate levels of mGlu2/3 receptors are found in the granule cell layer of the cerebellum, and the dorsal horn of the spinal cord.
Pharmacology of Group I mGlu receptors
The investigation of the respective functional roles for each mGlu receptor subtype requires the use of ligands which are not only group-or subtype-selective, but which also possess the adequate physico-chemical and pharmacokinetic properties needed for their use in different in vivo experimental models. Glutamate and aspartate are the two acidic representatives among the natural amino acids. The presence of a distal carboxylic acid enhances their polar properties in comparison to the other amino acids. These polar properties limit considerably their capacity to cross membranes by passive diffusion. Therefore, glutamate is actively transported through biological membranes by specific transporter proteins. To date, most mGlu receptor-selective ligands are amino acid derivatives. Despite the structural analogy to glutamic acid, the majority of these molecules fail to be transported actively through the cell membranes by the specific glutamate transporter systems. As a consequence, these compounds have a poor oral bioavailability, and do not readily cross the blood-brain barrier. Exceptions include the recently disclosed small molecular weight ligands, LY354740 and its derivative LY379268 (Fig. 4) , which display potent agonist activity at mGlu2/3 receptors, are orally bioavailable and enter the brain ; see also Johnson et al., 2002a) . In addition, non-amino acid Group I antagonists, such as the mGlu5 antagonist MPEP and the mGlu1 antagonist BAY36-7620 (Carroll et al., 2001) (Fig. 4) (3,5-dihydroxyphenylglycine) , and antagonists such as MCPG (a-methyl-4-carboxyphenyl-glycine), 4CPG (4-carboxy-phenylglycine), 4C3HPG (4-carboxy-3-hydroxy-phenylglycine), LY357366 ((RS)-3-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)ethyl]cyclobutanecarboxylic acid), and LY367385 (( + )-2-methyl-4-carboxyphenylglycine) (Nicoletti et al., 1996; Conn and Pinn, 1997; Bordi and Ugolini, 1999; Hölscher et al., 1999; Schoepp et al., 1999) . However, all these compounds are amino-acid derivatives, lack subtype selectivity, have a poor bioavailability, and scarcely penetrate the brain. A second group consists of noncompetitive ligands, which have no structural analogies to amino acids (Fig. 4) . The first example is the chromene derivative, 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester (CPCCOEt) (Litschig et al., 1999) , a small molecular weight compound with twentyfold selectivity for the mGlu1 over the mGlu5 subtype (IC 50 of 6.5 mmol/l at the human mGlu1b receptor). However, due to the lack of bioavailability and blood-brain barrier penetration, this derivative and its close analogues were only used for in vitro investigations. Novel mGlu1 selective, non-competitive antagonists such as BAY36-7620 ((3aS,6aS)-6a-naphthalen-2-ylmethyl-5-methyliden -hexahydro-cyclopenta[c]-furan-1-one; IC 50 = 0.16 mmol/l at the rat mGlu1a receptor), LY456236 ((4-methoxy-phenyl)-(6 methoxy quinazolin 4 yl) amine), R128494 (3-ethyl-2-methylquinolin-6-yl)-(4-hydroxy-cyclohexyl)-methanone, and pyrrole derivatives such as 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylic acid 2-propyl ester 4-((S)-1,2,2-trimethylpropyl) ester were described (Carroll et al., 2001; Mabire et al., 2002; Micheli et al., 2002) , and found to be useful tools for in vivo studies (Müller et al., 2000; Lesage et al., 2002; Li et al., 2002; Micheli et al., 2002) . In addition to these non-competitive antagonists, structurally novel compounds, which selectively potentiate glutamate activation of mGlu1 receptors, have been described recently (Knoflach et al., 2001) . These drugs interact within the transmembrane domain of the receptor, and enhance glutamate efficacy and affinity through a novel mechanism. This potentiation has been observed in vitro in recombinant cells expressing the rat mGlu1 receptor, as well as in rat brain native tissues.
mGlu5 receptor ligands
Up to now, only one competitive ligand, CHPG (2-chloro-5-hydroxyphenylglycine), has been described as a selective mGlu5 receptor agonist (Doherty et al., 1997) . However, like the competitive mGlu1 receptor agonists, this compound also possesses low potency, and lacks bioavailability and penetration of the blood-brain barrier. Although these properties limit considerably its utilization in animal models, CHPG has been used as a tool to investigate the selective function of mGlu5 receptors by means of intracerebroventricular injections (see below). Recently, Merck presented the first selective positive modulator for the mGlu5 receptor, DFB (3, 3 0 -difluorobenzaldazine), which potentiates glutamate responses in vitro (Williams et al., 2002) . No in vivo data were reported.
The first selective and structurally novel mGlu5 receptor antagonists identified were SIB-1757 [6-methyl-2-(phenylazo)-pyridin-3-ol] and SIB 1893 [(E)-2-methyl-6-styryl-pyridine]. In the phosphotidylinositol (PI) hydrolysis assay, these compounds have IC 50 values of 3.7 and 3.5 mmol/l, respectively (Varney et al., 1999) . Structural derivatization around these compounds and functional screening approaches led to the discovery of the first potent mGlu5 receptor selective (non-competitive) antagonist, MPEP (2-methyl-6-(phenylethynyl)-pyridine) Pagano et al., 2000) . MPEP is a highly potent mGlu5 receptor antagonist with an IC 50 value of 36 nMol, and with no appreciable agonist or antagonist activity at the closely related recombinant human mGlu1b receptor. Furthermore, MPEP showed no appreciable agonist or antagonist activity in cAMP accumulation or [
35 S]-GTPgammaS binding assays at the recombinant human Group II and III mGlu receptors. No activity was found at the human NMDA, rat AMPA, and human kainate receptors. In vivo studies performed with MPEP have shown that this compound is bioavailable and readily penetrates the brain . Very recently, a derivative of MPEP, MTEP (3-[2-methyl-1,3-thiazol-4-yl-ethynyl]pyridine), was described as a highly selective mGlu5 receptor antagonist Varney et al., 2002; Cosford et al., 2003) .
In vivo pharmacology of mGlu1 receptors
Activation of mGlu1 receptors leads to a potentiation of NMDA responses, which involves membrane depolarization. This leads to increases in cell excitability, which may be involved in processes of excitotoxicity (Nicoletti et al., 1996; Bordi and Ugolini, 1999; Bruno et al., 2001) , and therefore drug discovery efforts have focused on mGlu1 receptor antagonists for the treatment of neurodegenerative disorders. These compounds are expected to normalize the increase in glutamatergic activity in these diseases 262 Behavioural Pharmacology 2003, Vol 14 No 4 in a more selective manner, and without the side effects found with drugs acting directly upon ionotropic glutamatergic receptors. The rationale for the treatment of neurodegenerative disorders and other CNS diseases is further supported by the distribution of mGlu1 receptors in the mammalian brain, which are found in cortical areas, and limbic areas, such as the hippocampus (Shigemoto and Mizano, 2000) .
Due to the initial lack of selective ligands, the majority of behavioural studies were performed with non-selective mGlu1 receptor ligands, such as the antagonists MCPG, 4CPG and 4C3HPG, and the agonists (1S,3R)-ACPD and 3,5-DHPG. As these compounds possess additional affinity for other receptors (e.g. mGlu2, mGlu3 and/or mGlu5 receptors), their effects can not be attributed unequivocally to activation of mGlu1 receptors, and therefore this overview will focus on studies performed with more selective ligands, such as AIDA, CPCCOEt, BAY36-7620, LY367385, LY456236, and a series of novel quinoline derivatives from Johnson & Johnson Pin et al., 1999; Bruno et al., 2001; Carroll et al., 2001; Lesage et al., 2002; Li et al., 2002) . BAY36-7620 is of special interest, as it has been one of the first noncompetitive and relatively potent mGlu1 receptor antagonists that penetrated the blood-brain barrier and possessed no activity at mGlu2 or mGlu5 receptors (Carroll et al., 2001 ). In addition, it has been tested in a wide range of animal models for neurological and psychiatric disorders (Chapman et al., 2000a; De Vry et al., 2001; Schröder et al., 2002) (Table 2 ). For recent reviews on the pharmacology of the first-generation mGlu1 receptor ligands, see Nicoletti et al. (1996) , Conn and Pinn (1997), Ugolini (1999), and Hölscher et al. (1999) .
Neurodegenerative disorders Stroke
In view of the historically well-established role for glutamate and NMDA receptors in ischaemic brain damage, this has been the initial focus in drug discovery research for mGlu1 receptor antagonists. We here refer to Nicoletti et al. (1996) and, more recently, Bruno et al. (2001) for a review on mGlu receptor subtypes as targets for the therapy of neurodegenerative disorders. Results from in vivo studies generally support the potential neuroprotective properties of mGlu1 receptor antagonists initially found in in vitro preparations. Transient or permanent occlusion of the carotid arteries in gerbils is a widely used model of global ischaemia. In this model, the mixed mGlu1 receptor antagonist/mGlu2 receptor agonist, 4C3HPG, protects CA1 pyramidal neurons when given before permanent occlusion (Henrich-Noack et al., 1998) . However, in light of the neuroprotective activity of the mGlu2 receptor agonist LY354740 in the gerbil model (Bond et al., 1998) , the effects of 4C3HPG might involve agonist activity at mGlu2 receptors. The mGlu1 receptor antagonist, BAY36-7620, was neuroprotective in two rat stroke models: the mid cerebral artery occlusion model (MCAO), and the subdural haematome model (De Vry et al., 2001) . A quinoline derivative from Johnson & Johnson, R128494, also reduced total infarct volume in the rat MCAO model (Lesage et al., 2002) . In the gerbil occlusion model, BAY36-7620 lacked activity (Table 2) ; whereas two further mGlu1 receptor antagonists, AIDA and LY367385, were neuroprotective (Cozzi et al., 1997; Bruno et al., 1999) . Interestingly, AIDA was not only neuroprotective in a rat model of traumatic brain injury, but this apparently also led to improved recovery from motor dysfunction , thus supporting that antagonism at m Glu receptors may improve recovery of function.
Parkinson's and Alzheimer's disease Excitotoxicity has also been proposed to be involved in the pathogenesis of chronic neurodegenerative disorders, such as Parkinson's and Alzheimer's disease. The distribution of mGlu1 receptors in the basal ganglia, and the functional effects upon their activation, i.e. these receptors play an important role in the regulation of locomotor activity by interacting with dopaminergic neurotransmission (e.g. Attarian and Amalric, 1997; Rouse et al., 2000) , support the mGlu1 receptor as a target for the treatment of Parkinson's disease. The rationale for Alzheimer's disease is based largely upon the increase of the secretion of amyloid precursor protein by stimulation of mGlu1 receptors (e.g. Nitsch et al., 1998) . This is expected to lead to a reduction of b-amyloid formation and excitotoxic degeneration. Accordingly, mGlu1 receptor antagonists and agonists may be beneficial for the treatment of Parkinson's and Alzheimer's disease, respectively. Supportive data with selective compounds in disease models, such as MPTP-treated animals for Parkinson's disease or amyloid precursor protein-overexpressing mice for Alzheimer's disease, are awaited, to support that mGlu receptor ligands can ameliorate disease symptoms.
Epilepsy
Glutamate plays a key role in epileptogenesis , and involvement of mGlu1 receptors is supported by the observation that the agonists (1S,3R)-ACPD and 3,5-DHPG induce limbic seizures in mice and rats (Tizzano et al., 1993 (Tizzano et al., , 1995 . The antagonist 4C3HPG showed anticonvulsant activity in the audiogenic-induced convulsion model in mice (Thomsen et al., 1994) , and in rats genetically prone to epilepsy (Tang et al., 1997) . In both models, the mGlu1 receptor antagonists AIDA and LY367385 displayed anticonvulsant properties, and both compounds also reduced the incidence of spontaneous spike and wave discharges in lethargic lh/lh mice . AIDA antagonized pentylenetetrazole-induced seizures in mice (Thomsen and Dalby, 1998) . BAY36-7620 increased the threshold for pentylenetetrazole-induced seizures (De Vry et al., 2001) , displayed anticonvulsant activity in the audiogenic-induced convulsion model, and blocked 3,5-DHPG-induced seizures in mice (Chapman et al., 2000a) . Although the novel aminopyrimidine mGlu1 receptor antagonist LY456236 inhibited sound-induced clonic-tonic seizures and limbic seizures in a 6 Hz focal seizure model, it failed to affect pentylenetetrazoleinduced clonic seizures in mice (Shannon and Peters, 2002) .
Electrical kindling via electrodes implanted in the amygdala or hippocampus is a widely used model to evaluate the potential of drugs for the treatment of complex partial seizures and as a tool to investigate the pathophysiology of epileptogenesis (Meldrum, 2002) . Although not adequate for primary screening, due to its labour-intensive requirements, this is the most widely used model of epilepsy, because the mechanisms involved in kindling are considered relevant for human epilepsy. Glutamatergic neurotransmission is critically involved in the kindling model (Löscher, 1998) . mGlu1 mRNAs are changed in the hippocampus of amygdala-kindled rats (Akbar et al., 1996) , and it has been proposed that blocking intracellular Ca 2 + by mGlu1 receptor antagonism would interrupt the increased excitatory response of epileptic neurons. Consistent with this hypothesis, data with (1S,3R)-ACPD in the kindling model suggest that Group I agonists are proconvulsant (Löscher, 1998 and references therein) . The two studies that tested mGlu1 receptor antagonists in kindling models produced conflicting data. Whereas BAY36-7620 did not reverse the kindling process (Table 2 , Chapman, unpublished data), LY456236 decreased seizure duration and seizure severity in amygdala-kindled rats (Shannon and Peters, 2002) . The reason for this discrepancy is unclear, and further kindling studies are needed to elucidate the potential of mGlu1 receptor antagonists as a novel class of antiepileptic drugs.
Psychiatric disorders Schizophrenia
The glutamate hypothesis of schizophrenia states that a hypofunction in the glutamate system is the underlying cause of this devastating disorder (Carlsson et al., 2001 ). This hypothesis is largely based upon the ability of noncompetitive NMDA antagonists such as phencyclidine (PCP) to mimic positive and negative symptoms of schizophrenia (Javitt and Zukin, 1991) . Therefore, drug discovery efforts are often directed to reverse the behavioural effects of NMDA antagonists. In view of these hypotheses, agonism or antagonism of mGlu receptors is a way of modulating glutamate activity and, accordingly, such modulatory mechanisms can, at least theoretically, have antipsychotic potential.
Gating deficits have been observed in schizophrenia patients (e.g. Braff et al., 1978) and this has been hypothesized to reflect a loss of sensorimotor gating, which may lead to sensory flooding and cognitive fragmentation (e.g. Swerdlow et al., 1994 and references therein) . Prepulse inhibition (PPI) of the acoustic startle response is an experimental procedure frequently used for the assessment of sensory inhibition or gating in humans and animals. PPI refers to the phenomenon that presentation of a subthreshold stimulus (prepulse) shortly before an intense startling stimulus (pulse), results in activation of an inhibitory process that attenuates ('gates') the startle response. The relative decrease or suppression of startle amplitude is used as a measure of gating. That disruption of PPI of the acoustic startle reflex may provide a valid animal model of deficient sensorimotor gating in schizophrenic patients is suggested by its good face-, construct-and predictive validity (for a more detailed discussion, see Swerdlow et al., 1994; Geyer and Markou, 1995) .
The non-competitive NMDA antagonists, PCP, dizocilpine and ketamine, disrupt sensorimotor gating of the acoustic startle response. Mixed results have been obtained with mGlu receptor ligands (see also the sections on the in vivo pharmacology of mGlu5 and mGlu2 ligands). Microinjection of the mGlu1 receptor agonists 3,5-DHPG and (1S,3R)-ACPD into the nucleus accumbens disrupted PPI. These effects were reversed by the mixed mGlu1 antagonist/mGlu2 antagonist MCPG and by the dopamine antagonist haloperidol (Grauer and Marquis, 1999) . However, systemic injection with the mGlu1 receptor antagonist, BAY36-7620, failed to improve baseline PPI or to reverse disruption of PPI by PCP, dizocilpine or apomorphine (Table 2) . BAY36-7620 also failed to reverse the behavioural stimulation and stereotypies induced by the dopaminergic psychostimulants, apomorphine and amphetamine, but it attenuated licking and facial grooming induced by dizocilpine (De Vry et al., 2001) . That antagonism of mGlu1 receptors may attenuate the effects of NMDA antagonists was further supported by the finding that BAY36-7620 abolished the facilitation of intracranial self-stimulation by dizocilpine. These findings are consistent with the facilitation of NMDA receptor function by mGlu1 receptor activation in different in vitro assays (e.g. Fitzjohn et al., 1996; Rahman and Neumann, 1996; Heidinger et al., 2002) . However, not all behavioural effects of NMDA antagonists are affected similarly by mGlu1 receptor antagonists. For example, in a drug discrimination model, BAY36-7620 did not antagonize the discriminative stimulus effects of PCP (De Vry et al., 2001) . A potential explanation is that the modulatory effects of mGlu1 receptors depend on the brain location of the NMDA receptors underlying the particular behavioural effect of PCP or dizocilpine. Together, the available data do not support an antipsychotic potential for mGlu1 receptor antagonists.
Anxiety, depression and drug abuse
Relatively few studies have been performed with mGlu1 receptor antagonists in models for these diseases. Studies with BAY36-7620 in the shock-induced ultrasonic vocalization test and the rat forced swim test were not supportive for an anxiolytic or antidepressant potential for mGlu1 receptor antagonists (Table 2) . However, R128494
and four further quinoline derivatives increased punished drinking in a Vogel conflict test; whereas BAY36-7620 and LY387385 were inactive (Lesage et al., 2002) . Possibly, anxiolytic activity might have been missed with the latter compounds due to underdosing, since both drugs are less potent at the target, and they may possess worse pharmacokinetic properties than the Johnson & Johnson compounds. In line with this, R128494 reversed DHPGinduced scratching in gerbils at the same doses that were active in the Vogel test; whereas BAY36-7620 and LY387385 were inactive (Lesage et al., 2002) . The reversal of the dizocilpine-induced facilitation of intracranial self-stimulation by BAY36-7620 (De Vry et al., 2001) suggests that mGlu1 receptor antagonists may reduce the abuse potential of NMDA antagonists. Further studies should investigate whether this will be reflected in an attenuation of the positive reinforcing stimulus properties of non-competitive NMDA antagonists in selfadministration paradigms.
Cognitive disorders
In view of the prominent role of glutamatergic transmission in processes of neuronal plasticity, as illustrated by the disruption of long-term potentiation (LTP) by NMDA antagonists, several studies focused on the role of mGlu1 receptors in LTP. It was found that mGlu1 receptor ligands modulate neuronal plasticity (e.g. Manahan-Vaughan et al., 1999) and, together with the proposed role for LTP in the establishment of 'memory traces' during learning, this triggered the testing of mGlu1 receptor ligands in models for learning and memory. The earlier studies have been reviewed by Riedel (1996) and the emerging picture was that pretraining application of non-selective mGlu1 receptor antagonists, such as MCPG and 4CPG, disrupt memory formation in hippocampus-dependent, spatial learning tasks, such as the water maze and spatial alternation in the Y-maze (e.g. Richter-Levin et al., 1994; Balschun and Wetzel, 1998) . These findings are consistent with the disruption of LTP by BAY36-7620 and LY367385 (Manahan-Vaughan and Schuetz, 2002; Schröder et al., 2002) . In contrast, post-training application of mGlu1 receptor agonists such as (1S,3R)-ACPD and t-ADA amplified memory formation in the passive avoidance task and spatial alternation, respectively (Riedel et al., 1996) . (1S,3R)-ACPD and 3,5-DHPG reversed the impairment of lever press learning by the antagonist MCPG (Mathis and Ungerer, 1999) . However, until a selective agonist has become available, the potential of a mGlu1 receptor agonist for the treatment of cognitive dysfunction remains basically unproven. In this vein, recent findings with the more selective mGlu1 receptor antagonist AIDA even suggest that an antagonist might be beneficial for improving memory formation. Initially, it was found that AIDA impaired contextual fear conditioning (Nielsen et al., 1997) , and working memory in a three-panel runway retention (Ohno and Watanabe, 1998 Table 2 ), and LY367385 impaired working and reference memory as assessed in a radial-arm maze task (ManahanVaughan and Schuetz, 2002) . However, in a study specifically designed to address the effects of AIDA on short-and long-term memory, AIDA improved short-term memory by enhancing within-session performance in a three-choice test; whereas long-term memory in this model, as well as aversive context conditioning, were impaired (Christoffersen et al., 1999a, b) . In conclusion, depending upon which compound, task and treatment conditions are used, mGluR1 agonists can improve learning and memory; whereas antagonists can both improve and disrupt cognitive processes. It will be interesting to observe how these findings will relate to the clinic, and which testing conditions in the rat are most predictable for the effects of mGluR ligands in man.
Pain
High densities of Group I mGlu receptors are found in the dorsal horn of the spinal cord (see section on brain distribution of mGlu receptors, above), and agonists at these receptors, such as 3,5-DHPG, potentiate or even induce nociceptive behaviour in the rat (e.g. Fisher and Coderre, 1998) . Antisense against mGlu1 receptors reduced the development of neuropathic pain in rats with chronic constriction injury of the sciatic nerve, induced prolonged thermal analgesia in a tail-flick model, and reduced the electrophysiological effects of 3,5-DHPG in the spinal cord (Young et al., 1998; Fundytus et al., 2001) . Likewise, anti-rat mGlu1 receptor antibodies induced antinociceptive effects, especially in models for chronic pain (Fundytus et al., 1998) . Data from studies with mGlu1 receptor antagonists confirm the initial findings from studies with antisense and antibodies. In the hot plate in mice, AIDA showed mild analgesia, although this was no longer observed at higher doses (>0.1 mmol; Moroni et al., 1997). BAY36-7620 attenuated tactile allodynia and thermal hyperalgesia in a chronic constriction injury rat model of neuropathic pain (De Vry, 2002) . Likewise, LY367385 was found to be active in various models of persistent pain behaviour in rats. The compound attenuated formalin late-phase pain behaviour and reversed mechanical allodynia behaviour after L5/L6 spinal nerve ligation (Chung model; Simmons et al., 2001) . LY367385 attenuated both capsaicin and carrageenan-induced thermal hyperalgesia, and mechanical allodynia behaviour (Kalra et al., 2001) , suggesting efficacy against inflammatory pain states. R128494 and three further quinoline derivatives attenuated formalin latephase pain (Lesage et al., 2002) . In the same study, BAY36-7620 and LY368375 were inactive. 3,5-Dimethyl-1H-pyrrole-2,4-dicarboxylic acid 2-propyl ester 4-((S)-1,2,2-trimethyl-propyl) ester from a series of novel pyrrole mGlu1 receptor antagonists attenuated formalin early-and late-phase pain, and reversed carrageenaninduced thermal hyperalgesia and chronic constriction injury pain (Micheli et al., 2002) . Together, the preclinical data package suggests that mGlu1 receptor antagonists may hold great promise for the treatment of pain. Studies are now beginning to address the neuropharmacological mechanisms involved in the modulating effects of mGlu receptor activation on noxious stimulation. In the mouse formalin model of persistent pain, microinjection of 3,5-DHPG into the periaqueductal grey matter decreased especially late-phase paw licking behaviour, and this decrease of the nociceptive response was antagonized by the mGlu1 receptor antagonist, CPCCOEt (Maione et al., 2000) .
In vivo pharmacology of mGlu5 receptors Neurodegenerative disorders Neuroprotection
The role of mGlu5 receptors in neuroprotection is controversial. In in vitro studies, concentrations of MPEP which were 500-5000 fold above its IC 50 at mGlu5 receptors exhibited robust neuroprotective properties (Bruno et al., 2001) . However, since such high concentrations of MPEP can inhibit NMDA receptors, it is conceivable that at least part of these effects may be mediated through these receptors (O'Leary et al., 2000; see also Blaabjerg et al., 2002) . Similarly, controversial findings have been collected in in vivo studies. MPEP exhibited neuroprotective effects in a NMDA-induced toxicity model following intracerebroventricular injection (Bruno et al., 2000) , and in a transient global ischaemia model in gerbils upon intraperitoneal injection (see also Bao et al., 2001) . In contrast, MPEP was inactive in a MCAO model in rats, after intravenous application (Wiessner, unpublished observation). Finally, CHPGinduced activation of mGlu5 was shown to be neuroprotective in b-amyloid-induced neuronal death in primary neuronal cultures (Faden and Movseyan, 2002) . From these findings it is clear that additional studies using well-defined experiments are necessary to better define the role of the mGlu5 receptor in neuroprotection.
Parkinson's disease
Modulation of glutamate transmission with Group I metabotropic glutamate receptor antagonists was recently proposed as an alternative therapeutic approach to reduce overactive glutamatergic pathways in the basal ganglia in Parkinson's disease (Wichmann and Delong, 1998; Awad et al., 2001) . Particularly because of its strategic expression in key basal ganglia structures (see section on the distribution of mGlu5 receptors), the mGlu5 receptor was considered as a particularly interesting drug target. Awad et al. (2001) found that stimulation of Group I mGlu receptors induced excitation in neurons of the subthalamic nucleus, and that this effect was effectively inhibited by MPEP. In drug-induced models of Parkinson's disease, MPEP inhibited haloperidol-induced catalepsy and muscle rigidity (Ossowska et al., 2001) . In the unilateral 6-OHDA rat rotation model, MPEP did not induce a robust rotational response but rather affected turning preference resulting in significantly increased net rotations (Spooren et al., 2000a) . However, these data extend and confirm earlier findings indicating the involvement of mGlu receptors in turning behaviour (Sacaan et al., 1991 (Sacaan et al., , 1992 Smith and Beninger, 1996; Kearney et al., 1997 ; reviewed by Schoepp and Sacaan, 1994) . Adaptive changes may play a key role in the response to mGlu5 receptor antagonists since chronic, but not acute, treatment enhanced ipsilateral rotations in the unilateral 6-OHDA model . Likewise, 3 weeks of treatment with MPEP, but not acute treatment, reversed the severe akinetic deficits observed after partial, bilateral neurodegeneration of the nigrostriatal pathway by 6-OHDA infusion in the striatum (Amalric and Koob, 1987; Amalric et al., 1995) , in rats trained to depress a lever rapidly after a cue-stimulus in a reaction-time task . Interestingly, no potentiation of this MPEP effect was found with inactive doses of the NMDA antagonist MK-801 . These data, in turn, suggest that the effect of MPEP may not be mediated through NMDA receptors, but through distinct systems. Finally, some findings have been presented suggesting neuroprotective effects of MPEP in Parkinson's disease lesion models (methamphetamine, MPTP and 6-OHDA). These data, in turn, may indicate that mGlu5 receptor antagonists may have beneficial effects on the progression of Parkinson's disease (Battaglia et al., 2002) , but these findings wait to be further substantiated.
Epilepsy
Group I mGlu receptors are critically located postsynaptically to enhance cellular excitability via interactions with other excitatory postsynaptic processes (Lujan et al., 1996; Wong et al., 1999) . Transient activation of Group I receptors can indeed convert interictal bursts into seizure-length discharges (Merlin and Wong, 1996; Merlin, 1999) . Accordingly, in vivo non-selective Group I agonists, such as DHPG as well as the more selective mGlu5 receptor agonist CHPG, may act as convulsants when applied intracerebroventricularly (Tizzano et al., 1995; Camon et al., 1998; Thomson and Dalby, 1998; Chapman et al., 2000b) . Consequently, antagonists of mGlu5 receptors may have potential as anticonvulsants. Indeed, the selective mGlu5 receptor antagonists SIB1893 and MPEP suppress sound-induced seizures in DBA-2 mice, and clonic seizures in the lethargic mouse (Chapman et al., 2000b) . Furthermore, it was recently shown that in epileptogenesis, induction of long-lasting burst prolongation is critically dependent on the transient activation of mGlu5 receptors rather than mGlu1 receptors (however, see Randall et al., 2002) . This, in turn, suggests that antagonism of mGlu5 receptors may be a critical dependent variable to accomplish prevention of seizure prolongation (Merlin, 2002 ; see also Aronica et al., 2000) . The importance of mGlu5 receptors in epilepsy is further emphasized by the finding that human brain samples of epileptic tissue indeed exhibit a high mGlu5 receptor load (Aronica et al., 2002) . Further studies in models relevant for human epilepsy, such as the kindling model, are awaited, to further substantiate the potential of mGlu5 antagonists as a novel class of anticonvulsants.
Psychiatric disorders Schizophrenia
Consistent with the glutamate hypothesis of schizophrenia, pharmacological and developmental disruption of the glutamate neurotransmitter system is known to produce prepulse inhibition (PPI) deficits, i.e. an operational measure of sensorimotor gating and a process deficient in schizophrenics (see section on the role of mGlu1 receptors in schizophrenia). Given the fact that mGlu5 receptors are highly expressed in the hippocampal formation, an involvement in sensory gating may well be hypothesized. Nevertheless, MPEP at anxiolytic doses and above has no effect on the acoustic startle response or on PPI (Spooren et al., 2000c; Spooren, unpublished observation) , suggesting a minor role for mGlu5 receptors in sensorimotor gating deficits in schizophrenia. Henry and co-workers (2001) initially showed an increased startle response and an impaired PPI in mGlu5 receptor knockout mice, which persisted following cross-fostering and breeding on a C57Bl/6 background strain. When bred on a 129/CD1 background, no increase in startle and only a small reduction in PPI was found, and this could not be confirmed in a second test (Henry et al., 2002; see also O'Meara et al., 2002) . Accordingly, the role of mGlu5 in sensorimotor gating (deficits) is not yet clearly established and appears at present to be more tightly linked to developmental processes. However, the recent finding that MPEP was found to significantly potentiate PCP-induced locomotor activity and PPI disruption, signals the possible interaction of mGlu5 and NMDA receptors in sensorimotor gating, and provides further evidence for an involvement of mGlu5 receptors in schizophrenia (Kinney et al., 2002) .
Drug abuse
Both ionotropic and metabotropic glutamate receptors are involved in the behavioural effects of psychostimulants (Kim and Vezina, 1998; Vezina and Kim, 1999; Swanson and Kalivas, 2000) . mGlu5 receptors may be particularly involved in the reinforcing effects of cocaine, as these receptors were upregulated in the nucleus accumbens, i.e. the core of the limbic forebrain reward circuitry, following chronic cocaine administration (Ghasemzadeh et al., 1999) . In line with these findings, mGlu5 receptor knock-out mice appear insensitive to some of the behavioural effects of cocaine, as they did not selfadminister cocaine, and showed no increased locomotor activity following cocaine treatment (Chiamulera et al., 2001) . In line with these findings, the selective mGlu5 receptor antagonist, MPEP, dose-dependently decreased cocaine self-administration (Chiamulera et al., 2001) . Altogether, these findings suggest a significant contribution of mGlu5 receptors in the behavioural effects of cocaine and in cocaine addiction. In contrast, no effect was found with MPEP on nicotine-induced potentiation of brain stimulation (Harrison et al., 2002 ; see also Kenny et al., 2002) . Clearly, the mechanisms underlying the effects of MPEP on cocaine self-administration remain to be further elucidated. Meanwhile, a recent study by Popik and Wrobel (2002) , showed the inhibition by MPEP of morphine-induced conditioned place preference in rats. Although the mechanisms involved remain to be elucidated, mGlu5 receptors appear to play a significant role in the development of dependence to psychostimulants or other drugs of abuse.
Anxiety and depression
The effects of MPEP in various rodent anxiety models revealed that, with the exception of benzodiazepines, this drug exhibits the widest and most robust anxiolytic activity seen to date in pre-clinical models. MPEP displayed anxiolytic activity in unconditioned response tests, such as the elevated plus-maze (Spooren et al., 2000c; Tatarczynska et al., 2001a) , social exploration, marble burying and stress-induced hyperthermia, including the modified version of this test (Spooren et al., 2000c (Spooren et al., , 2002a ; reviewed by Spooren et al., 2001) . A very recent study elegantly showed that stress-induced hyperthermia was attenuated by MTEP in wild-type animals but not in mGlu5-receptor-knockout (KO) animals, underlining the selective involvement of mGlu5 receptors in these processes. Furthermore, it was found that mGlu5-receptor-KO animals exhibited reduced levels of anxiety, as measured by body temperature, in response to an intruder animal (Brodkin et al., 2002a) .
MPEP was also active in conditioned response tests, such as the Vogel conflict (Tatarczynska et al., 2001a; Schwarz et al., 2002; Spooren et al., 2002b) , four-plate test (Tatarczynska et al., 2001a) , Geller Seifter, ultrasonic vocalizations (Brodkin et al., 2002; Spooren et al., 2002b) , fear-potentiated startle (Schultz et al., 2001; Brodkin et al., 2002b; Spooren, unpublished observation) , experimental hypoxia (Nadlewska et al., 2002) , and conditional emotional response (Spooren et al., 2002b) . The anxiolytic activity of MPEP was maintained following chronic application Spooren et al., unpublished observation) . The exact mechanism of action and the role of mGlu5 receptors in anxiety are not fully elucidated yet, but it is apparent that the amygdala may play a key role (Schultz et al., 2001; Fendt and Schmid, 2002; Rodrigues et al., 2002) , and that the effect is independent of benzodiazepine receptors (Klodzińska et al., 2002; Schwarz et al., 2002) . As far as the safety margin is concerned, the anxiolytic dose range of MPEP in most of the above-mentioned studies was between 3 and 30 mg/ kg (p.o.), i.e. far below doses affecting spontaneous locomotor activity (>100 mg/kg, p.o.) or rotarod performance (>300 mg/kg, p.o.; Spooren et al., 2000a, c) . Clearly the scope of potential side-effects of mGlu5 receptor antagonists, including the anticipated effects on cognition (see below), should be explored in much more detail, but our current understanding of the action of mGlu5 receptor antagonists suggests that this class of compounds may hold promise as novel anxiolytics.
Antidepressant activity with MPEP was first observed in the tail suspension test, but MPEP was inactive in the forced swim test (Tatarczynska et al., 2001a) . Antidepressant activity was confirmed in the bulbectomy model of depression following chronic application, and using the passive avoidance test as a behavioural readout . Although these findings are encouraging, further testing in chronic depression models is warranted to substantiate these findings.
Cognitive disorders
Studies using Group I specific antagonists and knockout mice have suggested the involvement of mGlu1/5 receptors in long-term potentiation (LTP), long-term depression and memory formation (Aiba et al., 1994; Conquet et al., 1994; Nakanishi, 1994; Riedel, 1996; Sekiyama et al., 1996; Conn and Pinn, 1997; Lu et al., 1997) . In LTP studies, the level of tetanization appeared to determine the importance of these receptors; whereas in learning studies, complexity of the task was a key variable (Balschun and Wetzel, 1998; Wilsch et al., 1998; Balschun et al., 1999) . Mice lacking mGlu5 receptors showed impaired acquisition and use of spatial information in both the Morris water maze and contextual fear conditioning (Lu et al., 1997) . Nevertheless, at present the exact role of mGlu5 in behavioural studies is not well defined. Intracerebroventricular injection of MPEP 30 min before tetanization induced a rapid decline of potentiation; whereas the same dose caused a marked impairment of retention in Y-maze spatial alternation 24 h after training (Balschun and Wetzel, 2002) . MPEP was found to be inactive when injected immediately after the training session. Likewise, intracerebroventricular injection of MPEP before tetanization impaired LTP in the dentate gyrus, and repeated injection for 10 days led to an impairment of working memory and reference memory in an 8-arm radial-maze task (Manahan-Vaughan and Schuetz, 2002) . In contrast, it has also been reported that pre-training, systemic injections of MPEP had no effect on long-term acquisition of a spatial three-choice rewardfinding test (Petersen et al., 2002) . Apparent differences in critical variables such as dosing, route of administration, and brain concentrations may explain some of these discrepancies. Therefore, the exact effect of antagonists/ agonists/positive modulators in cognition await further investigation.
Pain mGlu5 receptors are found at the peripheral endings of the nociceptive C-fibre afferents, dorsal root ganglia and superficial dorsal horn neurons, i.e. at critical positions of the somatosensory neuraxis (Shigemoto and Mizuno, 2000) , suggesting their potential involvement in nociception. Accordingly, the Group I agonist DHPG and the mGlu5 receptor agonist CHPG induced mechanical hyperalgesia, which was reversed by MPEP injected into the inflamed paw (Walker et al., 2001a, b) . Comparable findings were obtained in the DHPG-induced thermal hypersensitivity test (Bhave et al., 2001) . Several lines of evidence suggest that mGlu5 receptors are primarily involved in nociception following tissue injury, rather then normal nociception. This was shown initially by Walker et al. (2001a) . Using the tail flick and paw pressure tests, MPEP was inactive in mechanical or thermal stimulation tests in naïve rats. In contrast, central or peripheral administration of MPEP into the inflamed paw reversed mechanical allodynia in the carrageenan and Freund's complete adjuvant models of inflammatory pain (Walker et al., 2001b) . Peripheral application of MPEP into the contralateral paw was ineffective. MPEP inhibited the second, but not the first, phase of the formalin pain test (Bhave et al., 2001) . Note that the first phase is caused by primary afferent activation; whereas the second phase reflects a combination of peripheral and central sensitization. In contrast to inflammatory-induced hypersensitivity, neuropathy-induced tactile allodynia and mechanical hyperalgesia appear unaffected (Dogrul et al., 2000; Walker et al., 2001a, b) , whereas weak effects were seen against thermal hyperalgesia (Hudson et al., 2002; Mills et al., 2002) .
These data suggest a central role for mGlu5 receptors in peripheral and central pain perception, and could therefore provide us with a potential novel target for pain control. However, the picture has been complicated by data from Merck, which indicated antihyperalgesic effects of MPEP in mGlu5-knockout mice (Varney et al., oral communication, 2002) . Therefore some of the studies should be revisited to more clearly define the role of the mGlu5 receptor in pain, preferably with drugs that have a different molecular structure than MPEP. Finally, it should be remembered that other glutamate receptors, particularly mGlu1 receptors, have also been implicated in peripheral and central pain processess (Young et al., 1998; Salt and Binns, 2000; Bhave et al., 2001) .
Pharmacology of Group II mGlu receptors mGlu2/3 receptor agonists and antagonists
As with Group I receptors, initial work was undertaken using non-selective ligands, such as MCPG (Group I/II antagonist), L-CCG-I (Group II agonist), (1S,3R)-ACPD (Group I/II agonist), DCG-IV (Group II agonist), which were not systemically active and required intracerebral or intraventricular administration. LY354740 was the first potent and selective agonist of Group II mGlu receptors, which had in vivo activity following systemic administration, both intraperitoneally and orally . The racemate is LY314582 and the inactive enantiomer is LY366563, which has been used to determine Group II receptor-mediated activity of LY354740. LY379268 is a more potent Group II agonist , and LY341495 is a Group II antagonist, with some affinity at the mGlu8 receptor (Kingston et al., 1998) . These compounds have become very useful tools for studying the role of Group II receptors in behavioural models. In addition, mice lacking the mGlu2 receptor are also available (Yokoi et al., 1996) , and these have also contributed to further improve our understanding of the role of Group II receptors. Recently, a mGlu Group IIreceptor-positive modulator with no intrinsic activity has been reported, LY487379 (Johnson et al., 2002a, b) .
In vivo pharmacology of mGlu2/3 receptors Since mGlu2 and mGlu3 receptors are predominantly located presynaptically, activation of these receptors results in a reduction in glutamatergic activity. This mechanism has led to an interest in developing ligands for these receptors for the treatment of disorders involving glutamate hyperactivity, such as neurodegeneration, anxiety and schizophrenia.
Neurodegenerative disorders Parkinson's disease
There are a few reports indicating that LY354740, and thus mGlu2 receptors, may have beneficial effects in Parkinson's disease. LY354740 was shown to inhibit muscle rigidity (Konieczny et al., 1998; Wolfarth et al., 2000) and catalepsy induced by haloperidol in rats. Since loss of nigrostriatal neurones in Parkinson's disease leads to increased activation of glutamatergic neurons in the subthalamic nucleus (STN), it is hypothesized that inhibition of glutamate release via presynaptic Group II mGluRs located in the STN may provide a novel therapeutic approach for this disorder .
Epilepsy Monn et al. (1997) first reported an anticonvulsant effect of LY354740 on ACPD-induced limbic seizures in mice, which was also enantiomer specific. Since then LY354740 has also been shown to inhibit both pentylenetetrazoland picrotoxin-induced convulsions in mice (Klodzińska et al., 2000) . LY354740 was also shown to potentiate slightly the anticonvulsant effect of diazepam, but not that of other antiepileptics tested, i.e. ethosuximide, valproic acid (Klodzińska et al., 2000) . It has also been shown that following amygdala kindling in rats, the inhibitory effects of Group II mGluR agonists are markedly increased, i.e. neurons within the amygdala are more sensitive to the drug effects (Neugebauer et al., 2000) . This study suggests that this class of compounds may be useful in the treatment of epilepsy; however, further work is required to determine this.
Psychiatric disorders Anxiety
It has been suggested that LY354740 inhibits sensitized glutamate release in brain areas considered to be part of the fear/anxiety circuitry (Bruijnzeel et al., 2001) . LY354740 produced a significant reduction of fearpotentiated startle in rats, whereas the inactive enantiomer, LY366563 had no effect (Helton et al., 1998) . The racemate, LY314582, reduced stress-induced hyperthermia in mice (Spooren et al., 2002a) . Furthermore, LY354740 significantly increased nose pokes and openarm activity, but not closed-arm activity, in the mouse plus-maze test; whereas the enantiomer had no effect. LY354740 also produced anxiolytic effects in the rat plusmaze, which were blocked by flumazenil, a benzodiazepine receptor antagonist (Ferris et al., 2001) . This latter study indicates that the anxiolytic effect produced by LY354740 may be directly or indirectly mediated by the GABAergic system. In contrast, flumazenil did not antagonize the effect of LY354740 on the reduced expression of the fear-potentiated startle response, at the same dose that blocked the effects of diazepam using the same test conditions (Tizzano et al., 2002a) . Tizzano et al. (2002a) suggested that fear suppression by diazepam and LY354740 requires different neuronal mechanisms.
LY354740 was active in the Vogel conflict drinking test in rats, and in the four-plate test in mice (Klodzińska et al., 1999) . Intra-hippocampal (CA1 area) administration of the Group II agonists, L-CCG-I and LY354740 produced an anxiolytic effect in the Vogel conflict drinking test in rats, with LY354740 being more potent than L-CCG-I (Tatarczynska et al., 2001b) . LY354740 reduced anxietylike behaviour in the defensive-withdrawal test performed 2 weeks after a session of inescapable footshocks (Bruijnzeel et al., 2001) . LY354740 prevented lactateinduced panic-like response in panic-prone rats (Shekhar and Keim, 2000) . These data could be substantiated in humans: LY354740 reduced panic anxiety induced by a CO 2 challenge in a small group of patients diagnosed with panic disorder. LY354740 also showed anxiolytic activity in patients with generalized anxiety disorder and in the fear-potentiated startle paradigm (Levine et al., 2002a, b; Grillon et al., 2003) .
These compounds are thought to have a better sideeffect profile compared to benzodiazepines such as diazepam, since they did not affect spontaneous locomotor activity in rats (Helton et al., 1998; Cartmell et al., 1999 , but see below), and had no effect on an accelerating rotarod in rats (Helton et al., 1998; Cartmell et al., 1999) and mice (Klodzińska et al., 1999) . Furthermore, there was no effect of LY354740 on hexobarbital-induced sleep time in mice and no pro-convulsant activity in mice by the racemate (Helton et al., 1998) . Recently, compounds with better oral potency in the fear-potentiated startle model were described, which should be useful for exploring the effects of mGluR2/3 agonists in other anxiety tests (Tizzano et al., 2002b) .
LY354740 was inactive on punished responding, but significantly increases time-out responding in a conflict task, and affected timing behaviour in a differential reinforcement of low rates task (Moore et al., 1999) . In line with these findings, it has been suggested by Schoepp et al. (1999) that LY354740 may have potential in psychiatric conditions associated with suppression of behaviours, such as social phobias, although further work is required in this area.
Schizophrenia
Activation of Group II mGlu receptors may provide a novel approach for the treatment of schizophrenia (Moghaddam and Adams, 1998; Cartmell et al., 1999) . Using non-selective compounds, infusion of Group I (3, , Group II (L-CCG-I), and Group I/II [(1S,3R)-ACPD] mGlu receptor agonists into the nucleus accumbens produced a disruption of PPI (Grauer and Marquis, 1999) . However, the first study that implicated mGlu2/3 receptor agonists in the treatment of schizophrenia showed that LY354740 blocked PCP-induced hyperactivity and stereotypy (particularly head rolls), and reduced PCP-induced glutamate release in the prefrontal cortex and nucleus accumbens (Moghaddam and Adams, 1998) . Other studies have confirmed this effect with both LY354740 and LY379268 (Cartmell et al., 1999 (Cartmell et al., , 2000a Bristow et al., 2002) , although LY379268 significantly reduces spontaneous activity at the same dose-range that blocks the PCP effects (Cartmell et al., 1999) . It was also shown that LY379268 specifically inhibited PCP-induced stereotypies, such as turning, head-weaving and backpedals (Cartmell et al., 2000a) . However, at the highest dose tested LY379268 significantly increased PCP-induced ataxia, which may also contribute to its overall effects (Cartmell et al., 2000a) . LY379268 has also been shown to reduce significantly ketamine and dizocilpineinduced hyperactivity , as well as amphetamine-induced hyperactivity in rats (Cartmell et al., 1999 (Cartmell et al., , 2000c Bristow et al., 2002) and mice (Bourson et al., 1999) . It has been shown recently that LY379268 has similar effects to clozapine in blocking PCP-induced effects in control and monamine-depleted rats (Swanson and Schoepp, 2002) . Compounds with enhanced oral potency in the PCP model have recently been presented (Johnson et al., 2002b) , which may provide a way of further exploring the activity of mGluR2/3 agonists in models of psychosis.
The effects of LY379268 in the PCP (Cartmell et al., 1999) and amphetamine (Cartmell et al., 2000c ) models were significantly reversed by LY341495, a Group II antagonist, indicating that these effects are mediated by mGlu2/3 receptors. Furthermore, LY314582 inhibited PCP-induced hyperactivity in wild-type mice, but not in mice lacking the mGlu2 receptor, indicating that its effects are mediated by mGlu2 receptors (Spooren et al., 2000b) . In addition, the reduction in spontaneous activity appears to be mediated via mGlu2 receptors, since LY314582 significantly reduced activity in wild-type mice, but not in mGlu2 receptor-knockout mice (Spooren et al., 2000b) . It is debatable whether these mGlu2/3 receptor agonists are counteracting the PCP effects in a behaviourally specific manner, since they also reduce spontaneous locomotor activity at doses that inhibit PCP effects in mice (Klodzińska et al., 1999; Spooren et al., 2000b) and rats (Cartmell et al., 1999; Moore et al., 1999; Ballard et al., 2001a) . It has been suggested that tolerance occurs for the motor impairment following sub-chronic dosing of LY379268, but not for the reversal of PCPinduced hyperactivity (Cartmell et al., 2000b) .
Aside from the locomotor effects, there is also controversy over the effects of mGlu2/3 receptor agonists in models of psychosis. Other groups have shown that LY354740 does not affect PCP-induced disruption of PPI Ballard et al., 2001a) , nor does it block the PCP cue in rats trained to discriminate PCP from vehicle (Bourson et al., 1999; Schreiber et al., 2000) . Using a hallucinogen (DOI) that activates 5-HT 2A receptors in vivo to produce head-shakes, LY354740 reduced, whereas LY341495 increased, the frequency of DOI-induced head-shakes (Gewirtz and Marek, 2000) . In contrast, LY354740 was unable to reduce LSD-induced hyperactivity and stereotypy (Ballard et al., 2001a) . Moreover, LY341495 did significantly increase LSDinduced activity (Ballard et al., 2001a) , which has been shown to be a 5-HT 2A mediated effect in vivo (Ouagazzal et al., 2001) . Since LY341495 also has affinity for mGlu8 receptor, further work with more selective mGlu2 agonists is required to confirm these effects. In conclusion: results with mGluR2 agonists from animal models for schizophrenia have been inconclusive, due to inconsistent effects, and potential confounds by their impairment of locomotor activity.
Drug abuse Helton et al. (1997) showed that LY354740 dosedependently inhibited the enhanced acoustic startle response induced by spontaneous nicotine withdrawal in chronically treated rats. In contrast, recent data have shown that another Group II agonist, LY314582, precipitated nicotine withdrawal (measured using intracranial self-stimulation, i.e. a measure of anhedonia) in rats, following systemic and direct injection into the ventral tegmental area, whereas the Group II antagonist, LY341495, prevented this withdrawal response (Kenny et al., 2002) . LY354740 has also been tested against morphine withdrawal and was able to dose-dependently suppress the severity and occurrence of the naltrexoneprecipitated behavioural signs of morphine withdrawal (Vandergriff and Rasmussen, 1999) . Since recent studies have shown that there is an alteration of synaptic plasticity involving glutamatergic synapses, particularly mGluR2/3, following either chronic morphine (Robbe et al., 2002) or cocaine treatment (Neugebauer et al., 2000) this indication should be investigated further. Furthermore, the effect of agonists and antagonists on drug withdrawal should be determined.
Cognitive disorders
LY354740 did not impair acquisition or retention (24 h) of a passive avoidance test in mice (Helton et al., 1998) , and did not impair conditioned avoidance responding during treatment or during drug withdrawal in rats (Helton et al., 1998) . In contrast, LY354740 produced a dose-and delaydependent impairment of working memory in a discrete paired-trial, variable-delay, T-maze task (Aultman and Moghaddam, 2001 ). The same authors have also shown that LY354740 improves the working memory deficit produced by PCP in an identical task, which suggests that the mechanism of action of this agonist in PCPtreated subjects differs from normal conditions (Moghaddam and Adams, 1998) . This is supported by a recent study in healthy human subjects, demonstrating that LY354740 dose-dependently attenuates ketamine-induced disruption of working memory (Krystal et al., 2002) .
Recently, Ballard et al. (2001b) have shown that LY354740 impairs working memory in an operant delayed-match-toposition (and delayed-non-match-to-position) task, and spatial learning in rats and wild-type mice. Furthermore, it was revealed that mGlu2 receptors were mediating the effects of LY354740, since the spatial learning deficit was not apparent in mice lacking the mGlu2 receptor. Without drug treatment these mice are unimpaired in a spatial learning task in the Morris water maze (Yokoi et al., 1996; Ballard et al., 2001b) . Further work is required in this area to understand the role of mGlu2 receptors in cognitive processes, in both impaired and unimpaired situations.
Synopsis and conclusions
The relatively recent identification of metabotropic glutamate receptors in the early 1990s opened up a novel possibility to target these receptors with drugs aimed at reversing the dysfunction of glutamatergic transmission that underlies certain CNS disorders. This new approach holds the promise for the discovery of drugs that modulate glutamatergic neurotransmission, instead of inducing a tonic activation or inhibition, as is achieved with drugs acting directly upon ionotropic glutamate receptors. As a consequence, agents acting through mGlu receptors might possess a larger safety window than agents acting at ionotropic glutamate receptors.
The high complexity of the expression of mGlu receptors and their distinct physiological role constitute a major challenge for attempts to unify the different pharmacological approaches and findings described in this paper. Nevertheless, the recent advances, achieved with the help of significant efforts in medicinal chemistry, allowed the identification of a number of novel agents, which, in turn, allowed the elucidation of the role of the different receptor subtypes in a variety of CNS disorders. These results have shed light on the different opportunities offered by pharmacological interactions with the Group I and II mGlu receptor subtypes.
For the mGlu1 receptor, significant progress was made recently thanks to the identification of potent and brain penetrant agents such as BAY36-7620, and the recently disclosed quinoline derivative, R128494. Promising beneficial effects could be demonstrated in animal models for acute neurodegenerative disorders, pain and anxiety. However, potential limitations, such as cognitive impairment, effects on motor coordination and sedation, have been seen, and will require special attention in the course of the clinical development of these agents.
In the case of the mGlu5 receptor, the extensive characterization of the prototypic antagonist MPEP allowed the identification of a number of potential indications for selective antagonists. Based on the wide and consistent effects of MPEP in animal models for either conditioned or innate fear in rodents, it can be hypothesized that mGlu5 receptor antagonists might be effective in humans for the treatment of anxiety-related disorders. This is strongly supported by the work of Rodrigues et al. (2002) , showing a key role for mGlu5 receptors in the lateral nucleus of the amygdala in the learning of fear. Additional potential indications could be inflammatory pain, Parkinson's disease and drug addiction, whereas antagonists may have a smaller potential for the treatment of acute degenerative processes (stroke) or epilepsy. Like mGlu1 receptors, mGlu5 receptors are expressed in key brain regions involved in cognitive processes, and their blockade could potentially inhibit certain forms of learning and memory. So far, and in contrast with results obtained with the mGlu5 nullmutant mice (Lu et al., 1997) , only central or local administration of MPEP induced cognitive deficits (Manahan-Vaughan and Schuetz, 2002) , whereas systemic administration showed no effects (Petersen et al., 2002) .
Finally, the use of activators of mGlu1 or mGlu5 receptors to enhance a deficient memory awaits a complete characterization of the recently disclosed positive modulators, in animal models for learning and memory.
The recent clinical evidence obtained with the mGlu2/3 agonist LY354740 demonstrates the usefulness of activation of Group II receptors for the treatment of anxietyrelated disorders (Levine et al., 2002a, b; Grillon et al., 2003) . In addition, these results increase the level of validation of the preclinical models in which LY354740 showed anxiolytic-like effects (Tizzano et al., 2002b) . This proof of principle with LY354740 also confirms that modulators at mGlu receptors display therapeutic activity at doses that are devoid of the side-effects typically observed with agents interacting with ionotropic glutamate receptors.
Given the fact that the first mGlu receptor was cloned barely 10 years ago, and taking into account the identification of non-amino-acid-like (small) molecules binding selectively to subtype specific mGlu receptors not much thereafter, one can state that considerable progress has been made within this field. Moreover, the highlighted recent advances in medicinal chemistry have indeed allowed the exploration of the therapeutic potential of subtype-specific ligands in disease models and even, most recently and excitingly, to study their effects in the clinic. These findings and developments have now launched a race to search for selective small molecules carrying all the characteristics of a true drug with the potential to treat specific nervous system disorders. Hopefully, this race will culminate soon in the launch of eagerly awaited more effective and much better-tolerated drugs, presenting patients with significant added value over current treatments.
